PureTech Health plc (PTCHF)
OTCMKTS · Delayed Price · Currency is USD
1.705
+0.005 (0.29%)
At close: Dec 29, 2025
PureTech Health Revenue
PureTech Health had revenue of $925.50K in the half year ending June 30, 2025, with 542.71% growth. This brings the company's revenue in the last twelve months to $6.39M, up 1,265.60% year-over-year. In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth.
Revenue (ttm)
6.39M
Revenue Growth
+1,265.60%
P/S Ratio
64.71
Revenue / Employee
114.13K
Employees
56
Market Cap
413.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
| Dec 31, 2017 | 2.54M | -1.90M | -42.79% |
| Dec 31, 2016 | 4.43M | -7.40M | -62.54% |
| Dec 31, 2015 | 11.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
PureTech Health News
- 13 days ago - PureTech Health (PRTC) Appoints Robert Lyne as CEO - GuruFocus
- 13 days ago - PureTech Health Appoints Robert Lyne As CEO; Focuses On Financing For Celea, Gallop Oncology - Nasdaq
- 13 days ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire
- 23 days ago - PureTech Health (PRTC) Sets Stage for Key Phase 3 Trial with FDA Approval - GuruFocus
- 23 days ago - PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 25 days ago - PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Business Wire
- 2 months ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire
- 3 months ago - Pres. Trump's deal with Pfizer is pretty devastating to PBMs and insurance companies: John Lamattina - CNBC